$1.43 +0.02 (%) Peregrine Pharmaceuticals Inc - NASDAQ

Nov. 21, 2014 | 04:00 PM

Partner Headlines

  1. Phase II Clinical Data Presented at SITC Annual Meeting Support Immunotherapeutic Mechanism of ...

    GuruFocus | Nov. 10, 2014 | 11:02AM EST
  2. Data to Be Presented at the SITC Annual Meeting Support Synergy of PS-Targeting and Anti-CTLA-4 ...

    GuruFocus | Nov. 7, 2014 | 11:03AM EST
  3. Promising Data Presented at the Chicago Multidisciplinary Symposium on Thoracic Oncology From ...

    GuruFocus | Oct. 30, 2014 | 12:03PM EST
  4. Morning Market Movers

    Benzinga | Oct. 15, 2014 | 09:48AM EST
  5. Earnings Scheduled For September 9, 2014

    Benzinga | Sep. 9, 2014 | 05:24AM EST
  6. Earnings Scheduled For July 14, 2014

    Benzinga | Jul. 14, 2014 | 05:33AM EST
  7. Peregrine Pharmaceuticals Announces Investigator-Sponsored Trial Combining Immunotherapy Bavituximab, Ipilimumab

    Benzinga | Apr. 23, 2014 | 07:31AM EST
  8. UPDATE: Peregrine Pharma Reports Data on Bavituximab Presented at AACR Validates Immune-Stimulatory Mechanism of Action

    Benzinga | Apr. 9, 2014 | 11:05AM EST
  9. Morning Market Movers

    Benzinga | Apr. 7, 2014 | 09:40AM EST
  10. Mid Morning Gainers for March 11th, 2014

    Benzinga | Mar. 11, 2014 | 11:20AM EST
  11. Mid-Afternoon Market Update: 3D Printing Names Take a Hit From Barron's Piece as Fuel Cell Names Continue Rally

    Benzinga | Mar. 10, 2014 | 15:50PM EST
  12. Mid-Day Market Update: Chiquita Gains On Merger News; Cliffs Natural Shares Drop

    Benzinga | Mar. 10, 2014 | 12:44PM EST
  13. Mid-Morning Market Update: Markets Open Lower; McDonald's Comparable Sales Fall 0.3%

    Benzinga | Mar. 10, 2014 | 10:35AM EST
  14. Earnings Scheduled For March 7, 2014

    Benzinga | Mar. 7, 2014 | 04:58AM EST
  15. Morning Market Movers

    Benzinga | Jan. 6, 2014 | 09:57AM EST
  16. Peregrine Pharmaceuticals Initiates Sunrise Pivotal Phase III Clinical Trial of Bavituximab in Second-Line Non-Small Cell Lung Cancer

    Benzinga | Dec. 30, 2013 | 07:37AM EST
  17. Earnings Scheduled For December 10, 2013

    Benzinga | Dec. 10, 2013 | 05:14AM EST
  18. Peregrine's Bavituximab in Combination With Anti-CTLA-4 Antibodies Yields Enhanced Anti-Tumor Activity in Pre-Clinical Model of Melanoma

    Benzinga | Nov. 8, 2013 | 09:10AM EST
  19. Peregrine Pharma Reports Results from Phase 2 Trial of Bavituximab, Says Topline Demonstrates Signs of Anti-Tumor Activity

    Benzinga | Feb. 13, 2013 | 01:36AM EST
  20. Peregrine Pharmaceuticals Finds Its Stride Again: Exclusive Interview With MLV & Co's George Zavoico

    Benzinga | Jan. 25, 2013 | 06:56AM EST
  21. Peregrine Pharmaceuticals Soars 80% on Study Review

    Benzinga | Jan. 8, 2013 | 00:28AM EST
  22. Major Averages Record Small Losses to Start Week

    Benzinga | Jan. 7, 2013 | 09:45AM EST
  23. Morning Market Movers

    Benzinga | Jan. 7, 2013 | 02:48AM EST
  24. Peregrine Regains Compliance With NASDAQ Minimum Bid Price Listing Requirement

    Benzinga | Dec. 11, 2012 | 08:03AM EST
  25. Earnings Scheduled For December 10, 2012

    Benzinga | Dec. 9, 2012 | 19:02PM EST
  26. The Week Ahead: Washington in Focus

    Benzinga | Dec. 7, 2012 | 09:37AM EST
  27. Ballots Are In: Worst CEO in the Biotech Industry Is . . .

    YCharts | Dec. 7, 2012 | 03:49AM EST
  28. Peregrine Shares Higher as Co. Reports Significant Progress in Advancing Cotara Program Into Pivotal Phase III Trial

    Benzinga | Dec. 5, 2012 | 02:19AM EST
  29. Benzinga's Microcap Movers for Wednesday October 17, 2012

    Benzinga | Oct. 17, 2012 | 14:07PM EST
  30. Milberg LLP Announces Pendency of Class Action Lawsuits Filed Against Peregrine Pharmaceuticals

    Benzinga | Oct. 5, 2012 | 09:03AM EST
  31. Benzinga Mid-Day Market Update

    Benzinga | Sep. 26, 2012 | 08:20AM EST
  32. Bronstein, Gewirtz & Grossman Announces Investigation of Peregrine Pharmaceuticals

    Benzinga | Sep. 25, 2012 | 02:33AM EST
  33. Benzinga Mid-Afternoon Market Update

    Benzinga | Sep. 24, 2012 | 09:51AM EST
  34. Mid-Day Market Losers

    Benzinga | Sep. 24, 2012 | 07:04AM EST
  35. Benzinga Mid-Day Market Update

    Benzinga | Sep. 24, 2012 | 06:58AM EST
  36. Morning Market Losers

    Benzinga | Sep. 24, 2012 | 05:08AM EST
  37. Peregrine Pharma Says Discovered Major Discrepancies in Control Group; Investors Shouldn't Rely on Phase 2 Data

    Benzinga | Sep. 24, 2012 | 01:32AM EST
  38. Benzinga's Top Pre-Market Gainers

    Benzinga | Sep. 10, 2012 | 02:07AM EST
  39. Earnings Scheduled For September 10, 2012

    Benzinga | Sep. 9, 2012 | 20:45PM EST
  40. Peregrine Pharma Says Phase II Trial Shows Doubling of Survival

    Benzinga | Sep. 7, 2012 | 06:54AM EST
  41. Peregrine Pharmaceuticals Secures $30 Million Loan Facility

    Benzinga | Aug. 30, 2012 | 09:21AM EST
  42. Health Care Sector Wrap

    FoxBusiness | Aug. 27, 2012 | 10:44AM EST
  43. Markwest Energy Partners, Dicks Sporting Goods Among Stocks Down on Above-average Volume Tuesday

    FoxBusiness | Aug. 14, 2012 | 06:33AM EST
  44. Peregrine Pharmaceuticals Soars After Smaller Than Expected Loss

    Benzinga | Jul. 17, 2012 | 07:24AM EST
  45. Peregrine Pharmaceuticals Inc. Reports Operating Results (10-K)

    GuruFocus | Jul. 16, 2012 | 13:18PM EST
  46. Earnings Scheduled For July 16

    Benzinga | Jul. 15, 2012 | 20:20PM EST
  47. Peregrine Pharmaceuticals Continues Strong Momentum; Shares up 14%

    Benzinga | Jul. 13, 2012 | 05:07AM EST
  48. Ultimate Stock Watch List for The Supreme Court's Health Care Ruling

    Benzinga | Jun. 28, 2012 | 03:51AM EST
  49. Avid Bioservices Announces Addition of Novel Bacteriophage

    Benzinga | Jun. 11, 2012 | 10:31AM EST
  50. UPDATE: Peregrine Says Preliminary Data From Phase II Study Shows Antiviral Activity and Positive Safety Profile at Both Bavituximab Doses Evaluated

    Benzinga | Dec. 29, 2011 | 01:02AM EST
Trading Center